In prostate cancer, SPOP mutation abrogates its interaction with the SRC-3 protein and subsequent regulation on AR transcription, leading to tumor progression and resistance to androgen deprivation therapies (Geng et al., 2013, 2017). This evidence concerns the gene SPOP and neoplasm.